Evaluation of Delirium Prevention in Critically Ill Patients

Radboud University Medical Center

Status: Completed

Conditions: Delirium

Study type: Observational

Funder types: Other

Identifiers

NCT01187667

2010/May

Details and patient eligibility

About

Haloperidol is prescribed in high risk ICU patients concerning delirium (50% or more chance to develop delirium detected with the delirium prediction model PRE-DELIRIC, or patients with history of dementia or alcohol abuse)since the delirium protocol is changed and haloperidol is added as a prevention treatment we are gathering information what the effect is on several aspects of delirium

Full description

Measurement the effect of haloperidol as delirium preventive intervention. Determining effect on:

• delirium incidence in the ICU - different subtypes of delirium - delirium free days in 28 days - days on the ventilator - length of stay on the ICU and In-Hospital - 28-day mortality - incidence of unexpected removal of tubes, and effect between different groups of patients. Safety of haloperidol concerning QT-time, extrapyramidal symptoms.

Data are compared with the data of a historical cohort

Enrollment: 650 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients With Predicted Delirium Chance of >50% or history of dementia or alcohol abuse and treated with haloperidol

Exclusion criteria

• CAM-ICU is Not Applicable
• Patients Admitted 24hours or Shorter on the ICU, Patients Who Are Delirious Within 24 Hours After ICU Admission
• patients whereby haloperidol is contra-indicated

Trial design

650 participants in 2 patient groups

Haloperidol prevention group

Description:

ICU patients with a high risk for delirium who are treated with haloperidol for preventive reason.

Control group

Description:

Historical cohort group of patients (2008-2009)with a determined risk of 50% or more for delirium who were not treated with haloperidol for preventive reason.